首页> 美国卫生研究院文献>Iranian Journal of Basic Medical Sciences >Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer
【2h】

Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer

机译:纳米脂质体介导的MDR1 siRNA传递降低乳腺癌细胞对阿霉素的抗性并沉默人乳腺癌异种移植模型中MDR1的表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective(s):P-glycoprotein (P-gp) is an efflux protein, the overexpression of which has been associated with multidrug resistance in various cancers. Although siRNA delivery to reverse P-gp expression may be promising for sensitizing of tumor cells to cytotoxic drugs, the therapeutic use of siRNA requires effective carriers that can deliver siRNA intracellularly with minimal toxicity on target cells. We investigated a special class of PEGylated lipid-based nanoparticles (NP), named nanolipoparticles (NLPs), for siRNA-mediated P-gp downregulation.
机译:目的:P-糖蛋白(P-gp)是一种外排蛋白,其过表达与多种癌症的多药耐药性有关。尽管为逆转P-gp表达而进行的siRNA递送对于使肿瘤细胞对细胞毒性药物敏感可能是有希望的,但siRNA的治疗用途需要能够在细胞内递送siRNA且对靶细胞毒性最小的有效载体。我们研究了一类特殊的聚乙二醇化脂质基纳米颗粒(NP),称为纳米脂质颗粒(NLP),用于siRNA介导的P-gp下调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号